
PAZOPANIB 400 mg (Pazinib) is a prescription targeted anticancer medicine used to treat advanced renal cell carcinoma, also known as kidney cancer, and certain types of advanced soft tissue sarcoma. It belongs to a class of medicines called tyrosine kinase inhibitors (TKIs) and works by blocking signals that promote cancer-cell growth and the formation of new blood vessels that supply tumours.
| Generic name | PAZOPANIB |
| Strength | 400 mg |
| Manufacturer | Hetero |
| Package size | 30 Tablets |
| Used for | Advanced renal cell carcinoma |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Pazopanib 400 mg works by inhibiting multiple tyrosine kinase receptors, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-KIT. By blocking these signalling pathways, it reduces the formation of new blood vessels that supply tumours and helps slow the growth and spread of cancer cells.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.